๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Trials with a site in Chengdu

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
NCT07615894Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
WestVac Biopharma Co., Ltd.
Phase 1
9
Chengdu
2026-06-01
Recruiting
Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors
NCT07563972Advanced Solid Tumors, Neoplasm
West China Hospital
Phase 1
9
Chengdu
2026-05-10
Recruiting
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
NCT06144671Advanced Solid Tumors
Grit Biotechnology
Phase 1/2
78
Shanghai, Chengdu
2025-11-01
Recruiting
HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
NCT06822998Advanced Solid Tumors
DrugHF50
HighField Biopharmaceuticals Corporation
Phase EARLY_PHASE1
10
Chengdu
2025-06-11
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
NCT06618651Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
162
Chengdu
2024-11-13
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
NCT06214143Advanced Solid Tumors
DrugT3011
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Recruiting
A Study of KC1036 in Patients with Advanced Solid Tumors
NCT04387916Advanced Solid Tumors
DrugKC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1
207
Chongqing, Haikou, Chengdu
2020-09-04
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Chengdu that also match the filters currently applied.

How many clinical trials are recruiting in Chengdu?

11 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chengdu), 13 studies
PhaseStudiesRecruitingShare
Phase 17553.8%
Phase 1/24430.8%
Phase EARLY_PHASE12215.4%

Most active sponsors

Lead sponsors with the most studies (Chengdu)
Lead sponsorStudiesRecruiting
Beijing Kanghong Biopharmaceutical Co., Ltd.10
Beijing Konruns Pharmaceutical Co., Ltd.11
CStone Pharmaceuticals11
Grit Biotechnology11
HighField Biopharmaceuticals Corporation11
MediLink Therapeutics (Suzhou) Co., Ltd.11
Merck Sharp & Dohme LLC11
Multitude Therapeutics Inc.11
Shanghai Pharmaceuticals Holding Co., Ltd11
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.